Developmental Outcome of Levetiracetam, Its Major Metabolite in Humans, 2‐Pyrrolidinone N‐Butyric Acid, and Its Enantiomer (R)‐α‐ethyl‐oxo‐pyrrolidine Acetamide in a Mouse Model of Teratogenicity (Q44597027)
Jump to navigation
Jump to search
scientific article published on October 1, 2003
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Developmental Outcome of Levetiracetam, Its Major Metabolite in Humans, 2‐Pyrrolidinone N‐Butyric Acid, and Its Enantiomer (R)‐α‐ethyl‐oxo‐pyrrolidine Acetamide in a Mouse Model of Teratogenicity |
scientific article published on October 1, 2003 |
Statements
1 reference
Developmental outcome of levetiracetam, its major metabolite in humans, 2-pyrrolidinone N-butyric acid, and its enantiomer (R)-alpha-ethyl-oxo-pyrrolidine acetamide in a mouse model of teratogenicity (English)
1 reference
Developmental Outcome of Levetiracetam, Its Major Metabolite in Humans, 2‐Pyrrolidinone N‐Butyric Acid, and Its Enantiomer (R)‐α‐ethyl‐oxo‐pyrrolidine Acetamide in a Mouse Model of Teratogenicity (English)
Nina Isoherranen
1 reference
Ofer Spiegelstein
1 reference
Meir Bialer
1 reference
Jing Zhang
1 reference
Michelle Merriweather
1 reference
Boris Yagen
1 reference
Michael Roeder
1 reference
Volker Schurig
1 reference
Aleata A. Triplett
1 October 2003
1 reference
1 reference
1 reference
Identifiers
1 reference